NASDAQ:CORV Correvio Pharma (CORV) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free CORV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.42▼$0.4250-Day Range$0.39▼$0.4252-Week Range$0.21▼$2.79VolumeN/AAverage Volume5.35 million shsMarket Capitalization$27.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Correvio Pharma alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Correvio PharmaCorrevio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.Read More Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. CORV Stock News HeadlinesMay 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)May 24, 2024 | msn.comTraws Pharma Showcases Promising COVID-19 Drug at ICAR ConferenceMay 16, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)May 15, 2024 | morningstar.comBig Pharma Split Corp Class AMay 13, 2024 | msn.comCorbus Pharmaceuticals a new outperform at RBC on cancer, obesity assetsMay 13, 2024 | markets.businessinsider.comPositive Outlook for Verona Pharma with Strong Financial Position and Anticipated Drug ApprovalMay 11, 2024 | businesswire.comCardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart FailureMay 10, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)May 9, 2024 | msn.comTraws Pharma Advances COVID-19 Treatment into First Human TrialsMay 9, 2024 | bizjournals.comRaleigh pharma secures $650M to be ready for growth surgeMay 7, 2024 | finance.yahoo.comNutra Pharma Corp. (NPHC)May 7, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 19, 2024 | wsj.comProtect Pharmaceutical Corp.April 16, 2024 | morningstar.comStella Pharma Corp Ordinary Shares 4888April 9, 2024 | msn.comNatco Pharma gets USFDA warning letter for Kothur plantMarch 29, 2024 | markets.businessinsider.comHold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing ConcernsMarch 19, 2024 | washingtonpost.comCorvus: Q4 Earnings SnapshotMarch 15, 2024 | bizjournals.com'This is a sleeping giant:' UC seals licensing deal with TRPV Pharmaceuticals for new heart failure drugMarch 13, 2024 | marketwatch.comCorbus Pharmaceuticals Stock Climbs on Narrower-Than-Expected 4Q LossMarch 1, 2024 | msn.comGarware Fulflex India acquires Avcor Health Care Products to strengthen its medical product portfolioFebruary 17, 2024 | wsj.comChong Kun Dang Pharmaceutical Corp.February 12, 2024 | finance.yahoo.comSilver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As PresidentJanuary 14, 2024 | morningstar.comChong Kun Dang Pharmaceutical CorpDecember 12, 2023 | seekingalpha.comCorvus Pharmaceuticals: Ahead Of The Clinical-Stage CurveDecember 7, 2023 | bizjournals.comAbbVie is acquiring two local biotechs — but won't detail its plans for themSee More Headlines Receive CORV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Correvio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/30/2020Today6/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CORV CUSIPN/A CIKN/A Webwww.correvio.com Phone604-677-6905FaxN/AEmployees133Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,180,000.00 Net Margins-107.81% Pretax MarginN/A Return on Equity-2,128.82% Return on Assets-58.56% Debt Debt-to-Equity Ratio22.54 Current Ratio1.07 Quick Ratio0.95 Sales & Book Value Annual Sales$32.63 million Price / Sales0.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-21.00Miscellaneous Outstanding Shares66,191,000Free FloatN/AMarket Cap$27.80 million OptionableOptionable Beta0.08 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Mark H. N. Corrigan (Age 62)CEO & Director Mr. Justin A. Renz CPA (Age 48)MST, M.S.T., MBA, CFO & Pres Ms. Sheila M. GrantChief Operating OfficerMr. David D. McMasters (Age 61)Chief Compliance Officer & Gen. Counsel Mr. Hugues SachotChief Commercial OfficerKey CompetitorsNeos TherapeuticsNASDAQ:NEOSAdicet BioNASDAQ:ACETCyteir TherapeuticsNASDAQ:CYTTAffimedNASDAQ:AFMDInterCureNASDAQ:INCRView All Competitors CORV Stock Analysis - Frequently Asked Questions How were Correvio Pharma's earnings last quarter? Correvio Pharma Corp (NASDAQ:CORV) announced its quarterly earnings results on Monday, March, 30th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The firm earned $11.33 million during the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative trailing twelve-month return on equity of 2,128.82%. What other stocks do shareholders of Correvio Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Inovio Pharmaceuticals (INO), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Heat Biologics (HTBX), Actinium Pharmaceuticals (ATNM), Acasti Pharma (ACST), Biocept (BIOC), Vaxart (VXRT), Co-Diagnostics (CODX). This page (NASDAQ:CORV) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredDouble-Threat Biotech Could Deliver Triple-Digit GainsMost investors haven't heard of this under-the-radar biotech... But it could emerge as one of the premier A...Behind the Markets | SponsoredA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Correvio Pharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Correvio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.